Drug intelligence / Profile preview

HS-10502 + irinotecan

Development stage: Unknown
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

HS-10502 + irinotecan is an investigational combination regimen of HS-10502, a *PARP1-specific selective inhibitor*, with irinotecan, a topoisomerase I inhibitor, being studied for advanced solid tumors. HS-10502 acts by selectively inhibiting Poly(ADP-ribose) polymerase 1 (PARP1), an enzyme involved in DNA repair, potentially enhancing the cytotoxicity of DNA-damaging agents like irinotecan and overcoming tumor cell resistance to chemo- and radiotherapy[1][4][5]. The combination aims to exploit synthetic lethality for cancers with homologous recombination deficiency, including breast, ovarian, gastric, and prostate cancer[1][2][3][5].

Other names: HS-10502 + irinotecan

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on HS-10502 + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10502 + irinotecan.

Explore the full profile